Introduction

The term Dry Eye Syndrome or dry eye disease has been defined as a multifactorial disease of the tears which results in symptoms of discomfort, visual disorders, and tear film uncertainty with potential damage to the ocular surface. The dry eye represents a disturbance of the lacrimal functional unit, an integrated system composed of the lacrimal glands, ocular surface (cornea, conjunctiva, eyelids, and therefore the meibomian glands) with the sensory and motor nerves that connect these structures.

The overall function of the lacrimal functional unit is to preserve tear film integrity, ocular surface health, maintaining corneal transparency, and surface somatic cell population; thereby, significantly influencing the quality of images projected onto the retina. Decreased tear secretion, delayed tear clearance from the ocular surface and altered tear composition may compromise tear film stability, sometimes amid ocular inflammation. Disturbances integral to the lacrimal functioning unit are considered to play an important role in the evolution of different forms of dry eye.

Dry Eye Syndrome or dry eye disease refers to a group of disorders of the ocular tear film attributed to reduced tear production or excessive tear evaporation, associated with ocular discomfort and /or visual symptoms with the possible disease of the ocular surface

Epidemiological information on dry eye syndrome has been restricted by lack of uniformity in its definition and therefore the incompetence of any single diagnostic assay or set of diagnostic tests to confirm or rule out the condition. Dry eye syndrome may be a common condition that causes varying degrees of discomfort and disability. Even though clinic-based studies confirm its frequency (17% of 2127 repeated new outpatients were diagnosed with dry eye following comprehensive examination), such studies might not replicate the general population.

Dry Eye Syndrome Treatment Market Overview

The global dry eye syndrome treatment market is estimated to expand at a higher rate over the forecast period. Increasing in the geriatric population is the major factor governing the market. According to the survey by Shire plc., it was observed that women above 50 years are more likely to be affected by dry eye disease. In addition to this, growing awareness about the diagnosis and treatment of the disease, a rise within the use of contact lenses, and therefore the rise in healthcare expenditure levels are estimated to boost the market.

The rising prevalence of eye disorders especially dry disease among the population is predicted to grow the market. The multi-screen modern lifestyle which includes eyestrain owing to the usage of mobile and computer screens are liable for causing eye-related problems. According to the survey proclaimed by Shire plc., around 9 in 10 eye care professionals believe that the above-mentioned reasons are the main reasons driving the dry eye syndrome testing market over the forecast period.

Common risk factors related to this syndrome are sex, age, environmental conditions, and autoimmune disorders with systemic medications. The presence of a good range of treatment options such as lubricant eye drops, punctual bags, artificial tears, and medicines for dry eye syndrome is predicted to fuel the growth of the market. However, the dearth of skilled ophthalmologists restrains the growth of the market. The symptoms of dry eye syndrome are common as other eye-related diseases at the early stage such as itchy eyes, burning sensation, heavy eyes, red eyes, sore eyes, and blurred vision. This creates a delay in detecting of dry eye disease.

Based on the sort, the dry eye syndrome treatment market is bifurcated into evaporative dry eye syndrome and aqueous dry eye syndrome. According to the survey published within the ARVO journal, evaporative dry eye syndrome is more common as compared to aqueous dry eye syndrome. On the idea of the treatment, the market is segmented into cyclosporine, corticosteroids, artificial tears, and punctual bags. According to the NCBI, among dry eye patients over 65 years aged, 25% apply artificial tears and 75% of them visited eye care professionals before starting any medications. Moreover, on the basis of distribution channels, the market is segmented as online pharmacies, hospital pharmacies, and retail pharmacies.

Dry Eye Syndrome Treatment Recent Developments

• In June 2019, Novartis completed the acquisition of Xiidra from Takeda Pharmaceutical Company Limited. This strategy would help the company to boost its ophthalmic portfolio in the market.
• In June 2019, Allergan participated at the Jefferies 2019 Healthcare Conference which was held in New York on 6th June. This helped the company to enhance its customer base.
• In December 2018, Alcon Inc. acquired Tear Film Innovations, Inc. (U.S.). The major advantage of this acquisition is that it is expected to help Alcon to expand its product portfolio in ocular health products and thus expanded its patient base by providing treatment for dry eye syndrome.

Competitive Landscape

As per the detailed report published by DataIntelo, the global dry eye syndrome treatment market is anticipated to expand at a CAGR of at least 6% during the forecast period 2020-2026.

Some of the major players operating in this market are Mitotech S.A, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., ALLERGAN, Novaliq GmbH, Prestige Consumer Healthcare, Inc., Horus Pharma, Senju Pharmaceutical Co. Ltd., VISUfarma, Akorn, Incorporated, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries Ltd., Alcon Inc., Santen Pharmaceutical Co., Ltd., Novartis AG, Similasan and others.

The post Dry Eye Syndrome Treatment Market Overview and Developments appeared first on Dataintelo.